Table of Content

1. Key Insights

2. Fragile X Syndrome (FXS): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of FXS in 2017
2.2. Total Market Share (%) Distribution of FXS in 2028

3. Disease Background and Overview: Fragile X Syndrome (FXS)
3.1. Introduction
3.2. Genomics
3.3. Symptoms
3.4. Clinical Features
3.5. Diagnosis
3.6. Fragile X and Newborn Screening
3.6.1. Recommendations for Diagnostic Testing
3.6.2. Differential Diagnosis

4. Epidemiology and Patient Population: Fragile X Syndrome
4.1. Key Findings
4.2. Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM
4.3. United States
4.3.1. Assumptions and Rationale
4.3.2. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United States
4.3.3. Gender-Specific Cases of Fragile X Syndrome (FXS) in the United States
4.3.4. Age-Specific Cases of Fragile X Syndrome (FXS) in the United States
4.4. EU5
4.5. Assumptions and Rationale
4.6. Germany
4.6.1. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Germany
4.6.2. Gender-Specific Cases of Fragile X Syndrome (FXS) in Germany
4.6.3. Age-Specific Cases of Fragile X Syndrome (FXS) in Germany
4.7. France
4.7.1. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in France
4.7.2. Gender-Specific Cases of Fragile X Syndrome (FXS) in France
4.7.3. Age-Specific Cases of Fragile X Syndrome (FXS) in France
4.8. Italy
4.8.1. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Italy
4.8.2. Gender-Specific Cases of Fragile X Syndrome (FXS) in Italy
4.8.3. Age-Specific Cases of Fragile X Syndrome (FXS) in Italy
4.9. Spain
4.9.1. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Spain
4.9.2. Gender-Specific Cases of Fragile X Syndrome (FXS) in Spain
4.9.3. Age-Specific Cases of Fragile X Syndrome (FXS) in Spain
4.10. United Kingdom (UK)
4.10.1. Total Diagnosed Prevalent Cases of Fragile X Syndrome in the United Kingdom
4.10.2. Gender-Specific Cases of Fragile X Syndrome in the United Kingdom
4.10.3. Age-Specific Cases of Fragile X Syndrome (FXS) in the United Kingdom
4.11. Japan
4.11.1. Assumptions and Rationale
4.11.2. Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Japan
4.11.3. Gender-Specific Cases of Fragile X Syndrome (FXS) in Japan
4.11.4. Age-Specific Cases of Fragile X Syndrome (FXS) in Japan

5. Current Treatment

6. Unmet Need

7. Emerging Drugs
7.1. Key Cross Competition
7.2. Cannabidiol: Zynerba Pharmaceuticals
7.2.1. Product Description
7.2.2. Other Developmental Activities
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. Acamprosate: Confluence Pharmaceuticals
7.3.1. Product Description
7.3.2. Other Developmental Activities
7.3.3. Clinical Development
7.3.4. Safety and Efficacy
7.3.5. Product Profile
7.4. BPN14770: Tetra Therapeutics
7.4.1. Product Description
7.4.2. Other Developmental Activities
7.4.3. Clinical Development
7.4.4. Safety and Efficacy
7.4.5. Product Profile
7.5. OV101: Ovid Therapeutics
7.5.1. Product Description
7.5.2. Other Developmental Activities
7.5.3. Clinical Development
7.5.4. Safety and Efficacy
7.5.5. Product Profile
7.6. Trofinetide: Neuren Pharmaceuticals
7.6.1. Product Description
7.6.2. Other Developmental Activities
7.6.3. Clinical Development
7.6.4. Safety and Efficacy
7.6.5. Product Profile

8. Market Size: Fragile X Syndrome
8.1. Key Findings
8.2. Total Market Size of Fragile X Syndrome in 7MM
8.3. Total Market Size of Fragile X Syndrome by Therapies in 7MM

9. Market Outlook: 7 MM
9.1. United States
9.1.1. The total market size of Fragile X Syndrome in the US
9.1.2. Total Market Size of Fragile X Syndrome by Therapies in the US
9.2. EU5
9.3. Germany
9.3.1. The total market size of Fragile X Syndrome in Germany
9.3.2. Total Market Size of Fragile X Syndrome by Therapies in Germany
9.4. France
9.4.1. The total market size of Fragile X Syndrome in France
9.4.2. Total Market Size of Fragile X Syndrome by Therapies in France
9.4.3. Italy
9.4.4. The total market size of Fragile X Syndrome in Italy
9.4.5. Total Market Size of Fragile X Syndrome by Therapies in Italy
9.5. Spain
9.5.1. The total market size of Fragile X Syndrome in Spain
9.5.2. Total Market Size of Fragile X Syndrome by Therapies in Spain
9.6. United Kingdom
9.6.1. The total market size of Fragile X Syndrome in the UK
9.6.2. Total Market Size of Fragile X Syndrome by Therapies in the UK
9.7. Japan
9.7.1. The total market size of Fragile X Syndrome in Japan
9.7.2. Total Market Size of Fragile X Syndrome by Therapies in Japan

10. Market Drivers

11. Market Barriers

12. KOL Views

13. Appendix
13.1. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight



List of Figures


Figure 1: The four alleles of the human FMR1 gene
Figure 2: Behavioral features of Fragile X Syndrome
Figure 3: Physical features of Fragile X Syndrome
Figure 4: Use of molecular techniques for Fragile X Syndrome (FXS) diagnosis
Figure 5: Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM (2017–2028)
Figure 6: Total Diagnosed Prevalent Cases of Fragile X Syndrome in the US (2017–2028)
Figure 7: Gender-Specific Cases of Fragile X Syndrome in the US (2017–2028)
Figure 8: Age-Specific Cases of Fragile X Syndrome in the US (2017–2028)
Figure 9: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Germany (2017–2028)
Figure 10: Gender-Specific Cases of Fragile X Syndrome in Germany (2017–2028)
Figure 11: Age-Specific Cases of Fragile X Syndrome in Germany (2017–2028)
Figure 12: Total Diagnosed Prevalent Cases of Fragile X Syndrome in France (2017–2028)
Figure 13: Gender-Specific Cases of Fragile X Syndrome in France (2017–2028)
Figure 14: Age-Specific Cases of Fragile X Syndrome in France (2017–2028)
Figure 15: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Italy (2017–2028)
Figure 16: Gender-Specific Cases of Fragile X Syndrome in Italy (2017–2028)
Figure 17: Age-Specific Cases of Fragile X Syndrome in Italy (2017–2028)
Figure 18: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Spain (2017–2028)
Figure 19: Gender-Specific Cases of Fragile X Syndrome in Spain (2017–2028)
Figure 20: Age-Specific Cases of Fragile X Syndrome in Spain (2017–2028)
Figure 21: Total Diagnosed Prevalent Cases of Fragile X Syndrome in the UK (2017–2028)
Figure 22: Gender-Specific Cases of Fragile X Syndrome in the UK (2017–2028)
Figure 23: Age-Specific Cases of Fragile X Syndrome in the UK (2017–2028)
Figure 24: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Japan (2017–2028)
Figure 25: Gender-Specific Cases of Fragile X Syndrome in Japan (2017–2028)
Figure 26: Age-Specific Cases of Fragile X Syndrome in Japan (2017–2028)
Figure 27: Unmet Need
Figure 28: Total Market Size of Fragile X Syndrome in 7MM in USD Million (2017-2028)
Figure 29: Total Market Size of FXS by Therapies in 7MM in USD Million (2017-2028)
Figure 30: Market size of Fragile X Syndrome in the US (2017–2028)
Figure 31: Total Market Size of FXS by Therapies in the US, in USD Million (2017-2028)
Figure 32: Market size of Fragile X Syndrome in Germany (2017–2028)
Figure 33: Total Market Size of FXS by Therapies in Germany, in USD Million (2017-2028)
Figure 34: Market size of Fragile X Syndrome in France (2017–2028)
Figure 35: Total Market Size of FXS by Therapies in France, in USD Million (2017-2028)
Figure 36: Market size of Fragile X Syndrome in Italy (2017–2028)
Figure 37: Total Market Size of FXS by Therapies in Italy, in USD Million (2017-2028)
Figure 38: Market size of Fragile X Syndrome in Spain (2017–2028)
Figure 39: Total Market Size of FXS by Therapies in Spain, in USD Million (2017-2028)
Figure 40: Market size of Fragile X Syndrome in the UK (2017–2028)
Figure 41: Total Market Size of FXS by Therapies in the UK, in USD Million (2017-2028)
Figure 42: Market size of Fragile X Syndrome in Japan (2017–2028)
Figure 43: Total Market Size of FXS by Therapies in Japan, in USD Million (2017-2028)
Figure 44: Market Drivers
Figure 45:Market Barriers


List of Tables


Table 1: Individuals for Whom Testing Should Be Considered for Fragile X syndrome diagnosis
Table 2: Total Diagnosed Prevalent cases of Fragile X Syndrome in 7MM (2017–2028)
Table 3: Total Diagnosed Prevalent Cases of Fragile X Syndrome in the US (2017–2028)
Table 4: Gender-Specific Cases of Fragile X Syndrome in the US (2017–2028)
Table 5: Age-Specific Cases of Fragile X Syndrome in the US (2017–2028)
Table 6: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Germany (2017–2028)
Table 7: Gender-Specific Cases of Fragile X Syndrome in Germany (2017–2028)
Table 8: Age-Specific Cases of Fragile X Syndrome in Germany (2017–2028)
Table 9: Total Diagnosed Prevalent Cases of Fragile X Syndrome in France (2017–2028)
Table 10: Gender-Specific Cases of Fragile X Syndrome in France (2017–2028)
Table 11: Age-Specific Cases of Fragile X Syndrome in France (2017–2028)
Table 12: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Italy (2017–2028)
Table 13: Gender-Specific Cases of Fragile X Syndrome in Italy (2017–2028)
Table 14: Age-Specific Cases of Fragile X Syndrome in Italy (2017–2028)
Table 15: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Spain (2017–2028)
Table 16: Gender-Specific Cases of Fragile X Syndrome in Spain (2017–2028)
Table 17: Age-Specific Cases of Fragile X Syndrome in Spain (2017–2028)
Table 18: Total Diagnosed Prevalent Cases of Fragile X Syndrome in the UK (2017–2028)
Table 19: Gender-Specific Cases of Fragile X Syndrome in the UK (2017–2028)
Table 20: Age-Specific Cases of Fragile X Syndrome in the UK (2017–2028)
Table 21: Total Diagnosed Prevalent Cases of Fragile X Syndrome in Japan (2017–2028)
Table 22: Gender-Specific Cases of Fragile X Syndrome in Japan (2017–2028)
Table 23: Age-Specific Cases of Fragile X Syndrome in Japan (2017–2028)
Table 24: Summary of medical problems and management
Table 25:Emerging Drugs Analysis
Table 26: Cannabidiol, Clinical Trial Description, 2019
Table 27: Acamprosate, Clinical Trial Description, 2019
Table 28: BPN14770, Clinical Trial Description, 2019
Table 29: OV101, Clinical Trial Description, 2019
Table 30: Trofinetide, Clinical Trial Description, 2019
Table 31: Total Market Size of Fragile X Syndrome in 7MM in USD Million (2017-2028)
Table 32: Total Market Size of FXS by Therapies in 7MM in USD Million (2017-2028)
Table 33: Total Market size of Fragile X Syndrome in the US (2017–2028)
Table 34: Total Market Size of FXS by Therapies in the US, in USD Million (2017-2028)
Table 35: Total Market size of Fragile X Syndrome in Germany (2017–2028)
Table 36: Total Market Size of FXS by Therapies in Germany, in USD Million (2017-2028)
Table 37: Total Market size of Fragile X Syndrome in France (2017–2028)
Table 38: Total Market Size of FXS by Therapies in France, in USD Million (2017-2028)
Table 39: Total Market size of Fragile X Syndrome in Italy (2017–2028)
Table 40: Total Market Size of FXS by Therapies in Italy, in USD Million (2017-2028)
Table 41: Total Market size of Fragile X Syndrome in Spain (2017–2028)
Table 42: Total Market Size of FXS by Therapies in Spain, in USD Million (2017-2028)
Table 43: Total Market size of Fragile X Syndrome in the UK (2017–2028)
Table 44: Total Market Size of FXS by Therapies in the UK, in USD Million (2017-2028)
Table 45: Total Market size of Fragile X Syndrome in Japan (2017–2028)
Table 46: Total Market Size of FXS by Therapies in Japan, in USD Million (2017-2028)